FDG–PET sensitivity for melanoma lymph node metastases is dependent on tumor volume
- 20 July 2001
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 77 (4) , 237-242
- https://doi.org/10.1002/jso.1102
Abstract
Background and Objectives The purpose of this study is to determine the tumor volume threshold for successful positron emission tomography (PET) imaging of melanoma nodal metastases. Methods Review of a clinical series of patients who had FDG–PET imaging of regional lymph node basins followed by lymphadenectomy. Lymph node tumor volumes were calculated from direct measurements of metastatic nodule(s) in formalin fixed specimens. PET scan interpretations were correlated with histology to determine sensitivity. Sensitivity was correlated with the aggregate lymph node tumor volume in the nodal basin and with AJCC stage group. Results Forty‐five patients with 49 pathologically positive regional nodal basins comprised the study group. Median total basin tumor volume was 28.3 mm3(range 0.004–22,879 mm3). FDG–PET sensitivity for detection of all tumor volumes was 0.49. The observed 90% sensitivity threshold for detection of nodal metastases was ≥ 78 mm3. PET sensitivity was 0.14 for detection of tumor volumes < 78 mm3. PET sensitivity differed by prescan AJCC stage: I—0.0; II—0.24; III—0.81; IV—1.0 (P < 0.001). Conclusions FDG–PET reliably detects lymph node tumor deposits greater than approximately 80 mm3 volume, but sensitivity falls rapidly below this. This amount of tumor is most likely to occur in patients with AJCC stage III or IV disease. J. Surg. Oncol. 2001;77:237–242.Keywords
This publication has 11 references indexed in Scilit:
- Positron emission tomography scanning in malignant melanomaCancer, 2000
- Lymph Node Tumor Volumes in Patients Undergoing Sentinel Lymph Node Biopsy for Cutaneous MelanomaAnnals of Surgical Oncology, 1999
- Prospective Study of Fluorodeoxyglucose–Positron Emission Tomography Imaging of Lymph Node Basins in Melanoma Patients Undergoing Sentinel Node BiopsyJournal of Clinical Oncology, 1999
- Primary staging and follow-up of high risk melanoma patients with whole-body18F-fluorodeoxyglucose positron emission tomographyCancer, 1998
- Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.Journal of Clinical Oncology, 1998
- Accuracy of positron emission tomography in staging patients with malignant melanomaMelanoma Research, 1997
- Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanomaJournal of Surgical Oncology, 1997
- Positron emission tomography in the detection and management of metastatic melanomaMelanoma Research, 1996
- Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 1995
- Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucoseBritish Journal of Dermatology, 1995